142 related articles for article (PubMed ID: 1572085)
1. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins.
Mühlebach TJ; Gabay J; Nathan CF; Erny C; Dopfer G; Schroten H; Wahn V; Seger RA
Clin Exp Immunol; 1992 May; 88(2):203-6. PubMed ID: 1572085
[TBL] [Abstract][Full Text] [Related]
2. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity.
Woodman RC; Erickson RW; Rae J; Jaffe HS; Curnutte JT
Blood; 1992 Mar; 79(6):1558-62. PubMed ID: 1312372
[TBL] [Abstract][Full Text] [Related]
3. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae.
Rex JH; Bennett JE; Gallin JI; Malech HL; DeCarlo ES; Melnick DA
J Infect Dis; 1991 Apr; 163(4):849-52. PubMed ID: 1901332
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease.
Bemiller LS; Roberts DH; Starko KM; Curnutte JT
Blood Cells Mol Dis; 1995; 21(3):239-47. PubMed ID: 8673477
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma in the treatment of the chronic granulomatous diseases of childhood.
Gallin JI
Clin Immunol Immunopathol; 1991 Nov; 61(2 Pt 2):S100-5. PubMed ID: 1934607
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease.
Ezekowitz RA; Orkin SH; Newburger PE
J Clin Invest; 1987 Oct; 80(4):1009-16. PubMed ID: 2821069
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular effects of recombinant interferon gamma in chronic granulomatous disease.
Newburger PE; Ezekowitz RA
Hematol Oncol Clin North Am; 1988 Jun; 2(2):267-76. PubMed ID: 2839459
[TBL] [Abstract][Full Text] [Related]
8. Chronic granulomatous disease with partial deficiency of cytochrome b558 and incomplete respiratory burst: variants of the X-linked, cytochrome b558-negative form of the disease.
Roos D; de Boer M; Borregard N; Bjerrum OW; Valerius NH; Seger RA; Mühlebach T; Belohradsky BH; Weening RS
J Leukoc Biol; 1992 Feb; 51(2):164-71. PubMed ID: 1431553
[TBL] [Abstract][Full Text] [Related]
9. Effect of interferon-gamma, in vitro and in vivo, on mRNA levels of phagocyte oxidase components.
Weening RS; de Klein A; de Boer M; Roos D
J Leukoc Biol; 1996 Dec; 60(6):716-20. PubMed ID: 8975873
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells.
Cassatella MA; Hartman L; Perussia B; Trinchieri G
J Clin Invest; 1989 May; 83(5):1570-9. PubMed ID: 2496143
[TBL] [Abstract][Full Text] [Related]
11. Effect of therapy with recombinant human interferon-gamma on the release of nitric oxide by neutrophils and mononuclear cells from patients with chronic granulomatous disease.
Condino-neto A; Muscará MN; Bellinati-Pires R; Carneiro-Sampaio MM; Brandão AC; Grumach AS; De Nucci G
J Interferon Cytokine Res; 1996 May; 16(5):357-64. PubMed ID: 8727075
[TBL] [Abstract][Full Text] [Related]
12. Chronic granulomatous disease.
Dinauer MC; Orkin SH
Annu Rev Med; 1992; 43():117-24. PubMed ID: 1316094
[TBL] [Abstract][Full Text] [Related]
13. NADPH-binding component of the respiratory burst oxidase system: studies using neutrophil membranes from patients with chronic granulomatous disease lacking the beta-subunit of cytochrome b558.
Tsunawaki S; Mizunari H; Namiki H; Kuratsuji T
J Exp Med; 1994 Jan; 179(1):291-7. PubMed ID: 8270871
[TBL] [Abstract][Full Text] [Related]
14. Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease.
Dinauer MC; Pierce EA; Erickson RW; Muhlebach TJ; Messner H; Orkin SH; Seger RA; Curnutte JT
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11231-5. PubMed ID: 1763037
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma in the management of chronic granulomatous disease.
Gallin JI
Rev Infect Dis; 1991; 13(5):973-8. PubMed ID: 1962114
[TBL] [Abstract][Full Text] [Related]
16. Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment.
Naderi beni F; Fattahi F; Mirshafiey A; Ansari M; Mohsenzadegan M; Movahedi M; Pourpak Z; Moin M
Int Immunopharmacol; 2012 Apr; 12(4):689-93. PubMed ID: 22330085
[TBL] [Abstract][Full Text] [Related]
17. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma.
Ezekowitz RA; Dinauer MC; Jaffe HS; Orkin SH; Newburger PE
N Engl J Med; 1988 Jul; 319(3):146-51. PubMed ID: 2838754
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood.
Sechler JM; Malech HL; White CJ; Gallin JI
Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4874-8. PubMed ID: 2838849
[TBL] [Abstract][Full Text] [Related]
19. NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system.
Condino-Neto A; Newburger PE
Arch Biochem Biophys; 1998 Dec; 360(2):158-64. PubMed ID: 9851826
[TBL] [Abstract][Full Text] [Related]
20. Chronic granulomatous disease in an adult female with granulomatous cheilitis. Evidence for an X-linked pattern of inheritance with extreme lyonization.
Dusi S; Poli G; Berton G; Catalano P; Fornasa CV; Peserico A
Acta Haematol; 1990; 84(1):49-56. PubMed ID: 2117330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
